Alexandra Cantley


Alexandra joined Polaris in 2019 and serves as a partner in the New York office. She is primarily focused on early stage biotech and healthcare investments.

She currently serves on the Board of Directors of Auron Therapeutics, BeMeHealth, Crossbow Therapeutics, EpiBiologics, Podimetrics, SunBird Bio, and TRex Bio, and as a Board Observer to Capstan Therapeutics and Engine Bio.

Prior to joining Polaris, Alexandra was part of the initial research team at Inzen Therapeutics, where she helped develop their platform technologies. She moved to Inzen from Vertex Pharmaceuticals, where she held a research fellowship.

Alexandra received a PhD in Chemical Biology from Harvard University, where she studied natural product discovery.  Alexandra performed her undergraduate studies at New York University.